Comparative study of alminoprofene elimination in healthy subjects and in patients with renal or hepatic insufficiency
Premel-Cabic, A.; Chaleil, D.; Bonniot, R.; Riberi, P.; Streichenberger, G.; Allain, P.
Therapie 36(1): 41-46
1981
ISSN/ISBN: 0040-5957 PMID: 7233371 Document Number: 172707
Plasma and urine alminoprofene concentrations were studied in 4 healthy subjects, 5 subjects with hepatic insufficiency and 5 subjects with renal insufficiency, after a 300 mg single oral dose. The elimination half-life, T1/2(.beta.), was significantly prolonged in patients with hepatic insufficiency (3.21 .+-. 0.40 h) and in patients with renal insufficiency (3.77 .+-. 1.02 h) compared to healthy subjects (2.36 .+-. 0.31 h). Alminoprofen is mainly excreted in urine as a conjugated drug; only 1.6 .+-. 0.8% of the dose was recovered as an unchanged product in healthy subjects and 57.1 .+-. 4.1% after enzymatic hydrolysis of urine. These results were not significantly different in hepatic insufficiency. Alminoprofene elimination is slightly impaired in patients with hepatic insufficiency or renal insufficiency; no dosage adaptation should be required in these patients.